VICD
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD)
Arms / Cohorts
Cohort A, Safety Lead-In:Bortezomib + Isatuximab + Cyclophosphamide + Dexamethasone
Accepting patients
Cohort A, Dose Expansion:Bortezomib + Isatuximab + Cyclophosphamide + Dexamethasone
Not yet accepting
Cohort B, Dose Expansion:Bortezomib + Isatuximab + Cyclophosphamide + Dexamethasone
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.